Shots:
- Corcept has reported P-III (ROSELLA) trial data assessing relacorilant (PO, GR antagonist) + nab-paclitaxel vs nab-paclitaxel in 381 pts with PROC
- Trial met its 1EP of OS, showing a 35% reduction in death risk (mOS: 16 vs 11.9mos.), & previously met its PFS endpoint with a 30% reduction in progression risk, as presented at ASCO 2025 & published in The Lancet;Â complete data to be presented in future
- Additionally, the FDA has assigned Jul 11, 2026, as the PDUFA date for relacorilant in PROC, while Corcept has also submitted an MAA to the EMA seeking approval for the same indication
Ref: Businesswire  |  Image: Corcept  | Press Release
Related News: Corcept Therapeutics Reports the EMA’s MAA Submission of Relacorilant to Treat Platinum-Resistant Ovarian Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
